$BIOXCEL Settlement: $9.75M Class Action Approved for Securities Fraud Claims
BioXcel Therapeutics settles $9.75M class action over securities purchased March-June 2023. Fairness hearing scheduled September 2026.
BTAIinvestor compensationsecurities litigation